BNET Industries
Market Cap:$864.1M
Last Fiscal Year Sales:$3.1M
- Public
- US
Dow Jones Description
We are a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. We are currently developing one product: KRYSTEXXA TM (pegloticase), as a therapy for patients with treatment-failure gout, or TFG, to control hyperuricemia and to manage the signs and symptoms of gout. TFG is gout in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. KRYSTEXXA is a biologic PEGylated uricase enzyme being developed for TFG to control hyperuricemia and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning and decreased frequency of flares. In October 2007, we completed the in-life portion of our two replicate Phase 3 clinical trials of KRYSTEXXA and we are currently conducting an open label extension, or OLE, study in patients who completed the Phase 3 clinical trials. In October 2008, we submitted a Biologic License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, for KRYSTEXXA and in December 2008, the FDA notified us that the BLA was accepted for priority review with a Prescription Drug User Fee Act action, or PDUFA, date of April 30, 2009. ...
Number of Employees 73
Contact Information
1 Tower Center 14th Fl
East Brunswick, New Jersey 08816
(732) 418-9300
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
Recent Events
-
JPMorgan Starts Savient SVNT at Overweight
-
Savient Pharmaceuticals SVNT Reports Q3 Loss of $0.23
-
Savient shares rise on takeover speculation
-
US SMALL/MIDCAPS-Tech stocks lift small, mid caps
-
Savient dips, but analyst expects 2010 drug launch
-
HEADLINE STOCKS-Some U.S. stocks on the move on Aug. 10
News & Analysis
Filter by
company and savient pharmaceuticals inc. - All News and Analysis
Savient to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
- 2008-01-22
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Christopher G. Clement, President and Chief Executive Officer, and Zeb Horowitz M.D., Chief Medical Officer of Savient Pharmaceuticals, will present a corporate update at the upcoming 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference that will...
Savient Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
- 2007-12-17
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that Christopher G. Clement, President and Chief Executive Officer and Zeb Horowitz M.D., Chief Medical Officer of Savient Pharmaceuticals will present a corporate update at the upcoming 26th Annual JP Morgan Healthcare Conference. The presentation is scheduled for 4:00...
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism 2007 Annual Congress
- 2007-06-06
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that two abstracts exploring Phase 2 Puricase([R]) (PEG-uricase) data and quality of life in treatment-failure gout patients will be presented at the European League Against Rheumatism EULAR 2007 Annual Congress taking place June 13 - 16th in Barcelona, Spain....
ROTH New York Conference 2006 Presenter Profiles
- 2006-09-01
NEW YORK -- ROTH New York Conference 2006 takes place September 6-7, 2006 at the Westin New York at Times Square. For in-depth information about the event, please visit http://www.rothconference.com/ . Below are profiles from ROTH New York Conference 2006 presenters. Breaking news releases are available at http://www.tradeshownews.com and...
Four Abstracts Accepted for Savient's Puricase® at European League Against Rheumatism 2006 Annual Congress
- 2006-04-19
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc., (NASDAQ: SVNT) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that four abstracts further detailing data on the Phase 2 clinical trial results of its drug development candidate, PuricaseR (PEG-uricase), and...
Savient's Puricase(R) (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients With Treatment-Resistant Gout.
- 2005-11-21
SAN DIEGO, November 21 /PRNewswire/ -- - Anecdotal Evidence Shows Resolution of Tophi - Phase 2 Data Presented at the 2005 Annual Meeting of the American College of Rheumatology Savient Pharmaceuticals, Inc. (Nasdaq: SVNTE) announced that patients with elevated blood uric...
Savient Pharmaceuticals Provides Business Update; Financial Overview and Recent Strategic Developments
- 2005-11-07
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc., (NASDAQ: SVNTE) an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, today provides a business and financial overview for the quarter ended September 30, 2005. Savient announced on...
Savient Pharmaceuticals Receives Filing Extension from Nasdaq
- 2005-10-28
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE), an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that the Nasdaq Listing Qualifications Panel (the "Panel") has agreed to continue the listing of the Company's securities on The Nasdaq...
Savient Pharmaceuticals Determines Periods Affected for Restatement Include Six Months Ended June 30, 2005 and Fiscal Years Ended 2004, 2003 and 2002
- 2005-10-26
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that the Company's Audit Committee, with the assistance of management, counsel and independent accounting consultants, and as discussed with its independent...
Savient Audit Committee Completes Review
- 2005-10-14
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that its Audit Committee has completed its review and investigation, with the assistance of management, counsel and independent accounting consultants, of...
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express